Introduction Undernutrition remains a major global health challenge, particularly in low-resource settings, and is closely linked to a complex gut disorder known as environmental enteropathy (EE). EE is characterised by impaired intestinal barrier function (“leaky gut”), inflammation, and reduced nutrient absorption, which together limit the effectiveness of nutritional interventions.
Introduction
Undernutrition remains a major global health challenge, particularly in low-resource settings, and is closely linked to a complex gut disorder known as environmental enteropathy (EE). EE is characterised by impaired intestinal barrier function (“leaky gut”), inflammation, and reduced nutrient absorption, which together limit the effectiveness of nutritional interventions. Accurate assessment of intestinal permeability is therefore crucial, but existing methods such as lactulose: rhamnose (LR) testing are cumbersome, invasive, costly, and difficult to implement at scale.
Problem Statement
Current diagnostic tools for evaluating gut barrier dysfunction in EE lack feasibility for widespread clinical and field use, especially in vulnerable populations like children and those in resource-limited regions. There is an urgent need for a rapid, reliable, non-invasive, and scalable method to assess intestinal permeability and overall gut function.
Summary
This study introduces transcutaneous fluorescence spectroscopy (TFS), a novel, non-invasive, sample-free technique that measures intestinal permeability through skin-based detection of fluorescent markers. TFS successfully differentiated increased gut permeability in Zambian participants with EE compared to healthy UK controls and showed a strong correlation with the conventional LR test (r≥0.78). Importantly, TFS allows simultaneous assessment of intestinal barrier integrity and gastric emptying without the need for biological sample collection. These findings position TFS as a promising tool for large-scale, real-time monitoring of gut health, particularly in low-resource settings, with potential applications beyond EE, including IBD and coeliac disease.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.